{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:52:37Z","timestamp":1775227957969,"version":"3.50.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The dynamic between pulmonary hypertension (PH) and COVID-19 has been under investigation since 2020, early in the pandemic. Although the pathophysiology of PH has been well-studied, new discoveries regarding the multisystemic effects of COVID-19 are still being uncovered. The cardiopulmonary effects of COVID-19 have led investigators to inquire about the interplay between these 2 conditions. Several factors are suggested to contribute to an increased risk of developing PH after infection with SARS-CoV-2. This includes cytokine storm, acute respiratory distress syndrome, and fibrotic changes seen in post-COVID-19 lung disease. Additionally, it has been proposed that certain medications used to treat PH may be applied to patients suffering from the cardiopulmonary complications of COVID-19. This review will focus on the interplay between COVID-19 and PH, with a special focus on the risk of developing PH after SARS-CoV-2 infection and the outcomes of patients with preexisting PH who are diagnosed with COVID-19. The potential benefits of utilizing off-label PH medications for COVID-19 patients will also be discussed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/crd.0000000000000679","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T09:03:10Z","timestamp":1708765390000},"page":"199-203","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 and Pulmonary Hypertension: An Interesting Dynamic"],"prefix":"10.1097","volume":"34","author":[{"given":"Saam","family":"Foroshani","sequence":"first","affiliation":[{"name":"From the Department of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Airo","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avi","family":"Levine","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg M.","family":"Lanier","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"key":"R1-20260403","doi-asserted-by":"crossref","first-page":"105951","DOI":"10.1016\/j.ijantimicag.2020.105951","article-title":"Coronavirus disease 2019 (COVID-19): current status and future perspectives.","volume":"55","author":"Li","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R2-20260403","doi-asserted-by":"crossref","first-page":"732690","DOI":"10.3389\/fimmu.2021.732690","article-title":"Angiotensin-converting enzyme 2 (ACE2) in the pathogenesis of ARDS in COVID-19.","volume":"12","author":"Kuba","year":"2021","journal-title":"Front Immunol"},{"key":"R3-20260403","first-page":"79","article-title":"Immunopathogenesis of Pneumonia in COVID-19.","volume":"19","author":"Alipoor","year":"2020","journal-title":"Tanaffos"},{"key":"R4-20260403","first-page":"425","article-title":"Ground-glass opacity: interpretation of high resolution CT findings.","volume":"106","author":"Battista","year":"2003","journal-title":"Radiol Med"},{"key":"R5-20260403","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"R6-20260403","first-page":"001784","article-title":"Unusually rapid development of pulmonary hypertension and right ventricular failure after COVID-19 pneumonia.","volume":"7","author":"van Dongen","year":"2020","journal-title":"Eur J Case Rep Intern Med"},{"key":"R7-20260403","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cytogfr.2021.10.003","article-title":"COVID-19 and dys-regulation of pulmonary endothelium: implications for vascular remodeling.","volume":"63","author":"Jadaun","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"key":"R8-20260403","first-page":"199","article-title":"Evidence of pulmonary hypertension after SARS-CoV-2 infection in subjects without previous significant cardiovascular pathology.","volume":"10","author":"Tudoran","year":"2021","journal-title":"J Clin Med Res"},{"key":"R9-20260403","first-page":"2045894020922799","article-title":"Could pulmonary arterial hypertension patients be at a lower risk from severe COVID-19?","volume":"10","author":"Horn","year":"2020","journal-title":"Pulm Circ"},{"key":"R10-20260403","doi-asserted-by":"crossref","first-page":"2045894020956581","DOI":"10.1177\/2045894020956581","article-title":"An unexpected recovery of patients with pulmonary arterial hypertension and SARS-CoV-2 pneumonia: a case series.","volume":"10","author":"Scuri","year":"2020","journal-title":"Pulm Circ"},{"key":"R11-20260403","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/diagnostics11010128","article-title":"COVID-19 in Pulmonary Artery Hypertension (PAH) patients: observations from a large PAH center in New York City.","volume":"11","author":"Sulica","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"R12-20260403","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1164\/rccm.202112-2761OC","article-title":"COVID-19 in patients with pulmonary hypertension: a national prospective cohort study.","volume":"206","author":"Montani","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"R13-20260403","first-page":"e0259","article-title":"Evaluation of the efficacy and safety of inhaled epoprostenol and inhaled nitric oxide for refractory hypoxemia in patients with coronavirus disease 2019.","volume":"2","author":"DeGrado","year":"2020","journal-title":"Crit Care Explor"},{"key":"R14-20260403","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1164\/rccm.202108-1855OC","article-title":"Prostacyclin in intubated patients with COVID-19 and severe endotheliopathy: a multicenter, randomized clinical trial.","volume":"205","author":"Johansson","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"R15-20260403","doi-asserted-by":"crossref","first-page":"81","DOI":"10.5152\/eurasianjmed.2020.19218","article-title":"Current pharmacological approach to ARDS: the place of bosentan.","volume":"52","author":"Araz","year":"2020","journal-title":"Eurasian J Med"},{"key":"R16-20260403","doi-asserted-by":"crossref","first-page":"340S","DOI":"10.1042\/CS103S340S","article-title":"Endothelin ET(B) receptor-mediated mechanisms involved in oleic acid-induced acute lung injury in mice.","volume":"103","author":"Guimar\u00e3es","year":"2002","journal-title":"Clin Sci"},{"key":"R17-20260403","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/jpm13111558","article-title":"The association of endothelin-1 with early and long-term mortality in COVID-19.","volume":"13","author":"Turgunova","year":"2023","journal-title":"J Pers Med"},{"key":"R18-20260403","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/2049-6958-8-74","article-title":"Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study.","volume":"8","author":"Araz","year":"2013","journal-title":"Multidiscip Respir Med"},{"key":"R19-20260403","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/andr.12837","article-title":"Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. the DEDALO project.","volume":"9","author":"Isidori","year":"2021","journal-title":"Andrology"},{"key":"R20-20260403","doi-asserted-by":"crossref","first-page":"112592","DOI":"10.1016\/j.biopha.2021.112592","article-title":"Pulmonary artery targeted therapy in treatment of COVID-19 related ARDS. literature review.","volume":"146","author":"Puk","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"R21-20260403","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ceca.2017.05.008","article-title":"Regulation of L-type CaV1.3 channel activity and insulin secretion by the cGMP-PKG signaling pathway.","volume":"66","author":"Sandoval","year":"2017","journal-title":"Cell Calcium"},{"key":"R22-20260403","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0039-6060(97)90009-X","article-title":"Nitric oxide attenuates platelet-activating factor priming for elastase release in human neutrophils via a cyclic guanosine monophosphate-dependent pathway.","volume":"122","author":"Partrick","year":"1997","journal-title":"Surgery"},{"key":"R23-20260403","article-title":"Effects of phosphodiesterase 5 inhibitor sildenafil on the respiratory parameters","volume":"69","author":"Kosutova","year":"2018","journal-title":"J Physiol Pharmacol"},{"key":"R24-20260403","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s00134-010-1754-3","article-title":"Sildenafil attenuates pulmonary arterial pressure but does not improve oxygenation during ARDS.","volume":"36","author":"Cornet","year":"2010","journal-title":"Intensive Care Med"},{"key":"R25-20260403","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3390\/v15051157","article-title":"Efficacy of sildenafil in patients with severe COVID-19 and pulmonary arterial hypertension.","volume":"15","author":"Oliynyk","year":"2023","journal-title":"Viruses"},{"key":"R26-20260403","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease.","volume":"384","author":"Waxman","year":"2021","journal-title":"N Engl J Med"},{"key":"R27-20260403","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R28-20260403","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1513\/AnnalsATS.202008-1002OC","article-title":"Persistent post-COVID-19 interstitial lung disease. an observational study of corticosteroid treatment.","volume":"18","author":"Myall","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"R29-20260403","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1056\/NEJMoa032274","article-title":"Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism.","volume":"350","author":"Pengo","year":"2004","journal-title":"N Engl J Med"},{"key":"R30-20260403","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/cts.12880","article-title":"The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective cohort study.","volume":"13","author":"Shi","year":"2020","journal-title":"Clin Transl Sci"},{"key":"R31-20260403","doi-asserted-by":"crossref","first-page":"101507","DOI":"10.1016\/j.jbc.2021.101507","article-title":"The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms.","volume":"298","author":"Paiardi","year":"2022","journal-title":"J Biol Chem"},{"key":"R32-20260403","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.jacc.2023.02.041","article-title":"Randomized trial of anticoagulation strategies for noncritically Ill patients hospitalized with COVID-19.","volume":"81","author":"Stone","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R33-20260403","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:07:26Z","timestamp":1775225246000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,24]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000679","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,24]]}}}